Evercore ISI Group Upgrades Akero Therapeutics to Outperform, Raises Price Target to $50
Evercore ISI Group analyst Liisa Bayko upgrades Akero Therapeutics (NASDAQ:AKRO) from In-Line to Outperform and raises the price target from $10 to $50.